Mechanisms of immune evasion and current status of checkpoint inhibitors in non-small cell lung cancer.

Mechanisms of immune evasion and current status of checkpoint inhibitors in non-small cell lung cancer.
复制标题

非小细胞肺癌的免疫逃逸机制及免疫检查点抑制剂的研究现状

DOI:
10.1002/cam4.819
复制
发表时间:
2016-09
期刊:
影响因子:
4
通讯作者:
Ramnath, Nithya
Ramnath, Nithya
中科院分区:
医学3区
文献类型:
--
作者:
Qin, Angel;Coffey, David G.;Warren, Edus H.;Ramnath, Nithya

文献摘要

参考文献

被引文献

相似文献

在过去的几年里,免疫疗法已成为晚期非小细胞肺癌(NSCLC)患者的一种可行的治疗选择,这些患者没有在标准化疗中进展的可操作的驱动突变。我们也开始了解NSCLC采用的免疫逃避方法,这可能有助于免疫治疗的20%应答率。目前还不清楚哪些肿瘤或患者因素预测免疫治疗的反应。本综述的目的是(1)审查NSCLC的免疫原性(2)描述免疫逃避机制(3)总结靶向抗程序性死亡-1(PD-1)和抗程序性死亡配体1(PD-L1)通路的努力(4)概述PD-1/PD-L1治疗应答的决定因素(5)讨论未来潜在的研究领域。
In the past several years, immunotherapy has emerged as a viable treatment option for patients with advanced non‐small cell lung cancer (NSCLC) without actionable driver mutations that have progressed on standard chemotherapy. We are also beginning to understand the methods of immune evasion employed by NSCLC which likely contribute to the 20% response rate to immunotherapy. It is also yet unclear what tumor or patient factors predict response to immunotherapy. The objectives of this review are (1) review the immunogenicity of NSCLC (2) describe the mechanisms of immune evasion (3) summarize efforts to target the anti‐program death‐1 (PD‐1) and anti‐program death‐ligand 1(PD‐L1) pathway (4) outline determinants of response to PD‐1/PD‐L1 therapy and (5) discuss potential future areas for research.
DOI: 10.1056/nejmoa1003466
发表时间: 2010-08-19
期刊: The New England journal of medicine
影响因子: --
作者:
Hodi FS;O'Day SJ;McDermott DF;Weber RW;Sosman JA;Haanen JB;Gonzalez R;Robert C;Schadendorf D;Hassel JC;Akerley W;van den Eertwegh AJ;Lutzky J;Lorigan P;Vaubel JM;Linette GP;Hogg D;Ottensmeier CH;Lebbé C;Peschel C;Quirt I;Clark JI;Wolchok JD;Weber JS;Tian J;Yellin MJ;Nichol GM;Hoos A;Urba WJ
通讯作者: Urba WJ
通过淋巴结消除来清除稳态细胞因子下沉,增强了采用转移的肿瘤特异性CD8+ T细胞的功效。
DOI: 10.1084/jem.20050732
发表时间: 2005-10-03
影响因子: 15.3
作者:
Gattinoni, Luca;Finkelstein, Steven E;Klebanoff, Christopher A;Antony, Paul A;Palmer, Douglas C;Spiess, Paul J;Hwang, Leroy N;Yu, Zhiya;Wrzesinski, Claudia;Heimann, David M;Surh, Charles D;Rosenberg, Steven A;Restifo, Nicholas P
通讯作者: Restifo, Nicholas P
CD8+ T细胞和CD4+ T细胞的同时浸润是非小细胞肺癌中的一个有利的预后因素。
DOI: 10.1038/sj.bjc.6602934
发表时间: 2006-01-30
影响因子: 8.8
作者:
通讯作者: --
肿瘤浸润的调节性T细胞抑制内源性细胞毒性T细胞对肺腺癌的反应。
DOI: 10.4049/jimmunol.1301317
发表时间: 2013-08-15
期刊: Journal of immunology (Baltimore, Md. : 1950)
影响因子: --
作者:
Ganesan AP;Johansson M;Ruffell B;Yagui-Beltrán A;Lau J;Jablons DM;Coussens LM
通讯作者: Coussens LM
DOI: 10.3389/fimmu.2013.00154
发表时间: 2013
影响因子: 7.3
作者:
Hebeisen M;Oberle SG;Presotto D;Speiser DE;Zehn D;Rufer N
通讯作者: Rufer N